drugset
drugset / Trial / NCT05724355

CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC

NCT05724355 ↗

Phase 2 Unknown 32 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Because most patients with R/M NPC have received long-term maintenance of immunotherapy at the time of initial treatment and the first-line treatment, there are a large number of PD-1 inhibitor refractory patients. How to deal with the ICIs resistance is an urgent problem in clinical practice.

Timeline

Start
2022-09-01
Primary completion
2023-10
Completion
2024-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Dalpiciclib Small molecule 150 mg Oral

Indications

nasopharyngeal carcinoma